Corvus starts Phase 1b trial of soquelitinib in hidradenitis suppurativa patients

• Corvus Pharmaceuticals began enrolling a Phase 1b trial of soquelitinib in hidradenitis suppurativa, expanding development beyond its current programs.
• No results have been presented; safety and early signs of clinical benefit are expected once the 12-week treatment period is completed.
• Study targets up to 25 adults with moderate to severe disease, aiming to support an oral option with a novel immune-modulating approach.
• Program adds a fourth clinical indication for soquelitinib, alongside late-stage work in peripheral T cell lymphoma and mid-stage trials in atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301605PRIMZONEFULLFEED9837291) on September 30, 2026, and is solely responsible for the information contained therein.